Nutriband Inc. (NTRB)
NTRB Stock Price Chart
Explore Nutriband Inc. interactive price chart. Choose custom timeframes to analyze NTRB price movements and trends.
NTRB Company Profile
Discover essential business fundamentals and corporate details for Nutriband Inc. (NTRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Oct 2021
Employees
13.00
Website
https://nutriband.comCEO
Gareth Sheridan
Description
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
NTRB Financial Timeline
Browse a chronological timeline of Nutriband Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 11 Jun 2026
EPS came in at -$0.10 , while revenue for the quarter reached $433.40k .
Earnings released on 29 Apr 2026
EPS came in at -$0.04 surpassing the estimated -$1.89 by +97.88%, while revenue for the quarter reached $400.71k , missing expectations by -47.62%.
Earnings released on 16 Dec 2025
EPS came in at -$0.12 surpassing the estimated -$2.13 by +94.37%, while revenue for the quarter reached $346.06k , missing expectations by -48.73%.
Earnings released on 9 Sept 2025
EPS came in at -$2.12 falling short of the estimated -$0.17 by -1.15k%, while revenue for the quarter reached $622.00k , meeting expectations.
Earnings released on 30 May 2025
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $667.00k , meeting expectations.
Earnings released on 28 Apr 2025
EPS came in at -$0.18 falling short of the estimated -$0.12 by -50.00%, while revenue for the quarter reached $642.00k , meeting expectations.
Earnings released on 3 Dec 2024
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $646.00k , missing expectations by -9.01%.
Earnings released on 3 Sept 2024
EPS came in at -$0.12 falling short of the estimated -$0.05 by -140.00%, while revenue for the quarter reached $442.83k , missing expectations by -34.40%.
Earnings released on 31 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.07 by -200.00%, while revenue for the quarter reached $408.53k , missing expectations by -27.46%.
Earnings released on 30 Apr 2024
EPS came in at -$0.16 falling short of the estimated -$0.07 by -128.57%, while revenue for the quarter reached $524.61k , missing expectations by -6.85%.
Earnings released on 12 Dec 2023
EPS came in at -$0.22 falling short of the estimated -$0.12 by -83.33%, while revenue for the quarter reached $427.84k , missing expectations by -6.20%.
Earnings released on 11 Sept 2023
EPS came in at -$0.11 falling short of the estimated -$0.08 by -42.60%, while revenue for the quarter reached $655.93k , beating expectations by +37.25%.
Earnings released on 9 Jun 2023
EPS came in at -$0.13 surpassing the estimated -$0.22 by +41.67%, while revenue for the quarter reached $476.93k , beating expectations by +4.65%.
Earnings released on 26 Apr 2023
EPS came in at -$0.21 falling short of the estimated -$0.05 by -320.00%, while revenue for the quarter reached $527.54k , missing expectations by -21.85%.
Earnings released on 2 Dec 2022
EPS came in at -$0.14 falling short of the estimated -$0.07 by -100.00%, while revenue for the quarter reached $620.00k , beating expectations by +10.09%.
Earnings released on 7 Sept 2022
EPS came in at -$0.12 falling short of the estimated -$0.07 by -71.43%, while revenue for the quarter reached $456.12k , beating expectations by +0.01%.
Stock split effective on 12 Aug 2022
Shares were split 583 : 500 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 May 2022
EPS came in at -$0.08 falling short of the estimated -$0.08 by -3.71%, while revenue for the quarter reached $477.91k , meeting expectations.
Earnings released on 29 Apr 2022
EPS came in at -$0.20 falling short of the estimated -$0.09 by -122.22%, while revenue for the quarter reached $491.90k , beating expectations by +7.93%.
Earnings released on 14 Dec 2021
EPS came in at -$0.23 falling short of the estimated -$0.03 by -666.67%, while revenue for the quarter reached $283.04k , missing expectations by -68.20%.
Earnings released on 3 Sept 2021
EPS came in at -$0.07 falling short of the estimated $0.01 by -800.00%, while revenue for the quarter reached $213.74k , missing expectations by -88.89%.
NTRB Stock Performance
Access detailed NTRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
